E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 10/6/2015 in the Prospect News Private Placement Daily.

New Issue: Nektar Therapeutics places $250 million of five-year notes with TPG Special Situations

By Lisa Kerner

Charlotte, N.C., Oct. 6 – Nektar Therapeutics closed a private placement of $250 million of 7.75% senior secured notes due in 2020 with investment vehicles managed by affiliates of TPG Special Situations Partners.

A portion of the proceeds was used to redeem all of Nektar’s currently outstanding $125 million of 12% senior secured notes due 2017.

“This transaction significantly reduced our cost of borrowing and avoided the dilutive effect of an equity or convertible debt offering,” said Nektar president and chief executive officer Howard Robin in a news release. “We have strengthened our financial position and now expect to have greater than $305 million in cash and equivalents at the end of 2015.”

Interest is payable quarterly in arrears on Jan. 15, April 15, July 15 and Oct. 15, beginning on Oct. 15.

Nektar may redeem some or all of the notes at any time prior to Oct. 5, 2017 by paying a make-whole premium, plus accrued and unpaid interest to the date of redemption.

Beginning of Oct. 5, 2017, Nektar may redeem some or all of the notes at a redemption price equal to 104% of the principal amount of the notes to be redeemed if the redemption date is prior to Oct. 5, 2018, 102% of the principal amount of the notes to be redeemed if the redemption date is prior to Oct. 5, 2019, or 100% of the principal amount of the notes to be redeemed if the redemption date is on or after Oct. 5, 2019, plus, in each case, accrued and unpaid interest to the applicable redemption date.

Nektar is required to maintain a minimum cash balance of $60 million, according to a form 8-K filed with the Securities and Exchange Commission.

The offer and sale of the notes is exempt from the registration requirements of the Securities Act of 1933.

Nektar is a drug development company based in San Francisco.

Issuer:Nektar Therapeutics
Issue:Senior secured notes
Amount:$250 million
Maturity:Oct. 5, 2020
Coupon:7.75%
Distribution:Private placement
Purchaser:Investment vehicles managed by affiliates of TPG Special Situations Partners

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.